Circulating KCNH2 Current-Activating Factor in Patients with Heart Failure and Ventricular Tachyarrhythmia

Hiroki Sugiyama1*, Kazufumi Nakamura1✉, Hiroshi Morita1,2, Satoshi Akagi1, Yoshinori Tani1, Yusuke Katayama1, Nobuhiro Nishii1, Toru Miyoshi1,2, Satoshi Nagase1, Kunihisa Kohno1, Kengo Fukushima Kusano1, Tohru Ohe1, Junko Kurokawa3, Tetsushi Furukawa3, Hiroshi Ito1

1 Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 2 Department of Cardiovascular Therapeutics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 3 Department of Bio-Informational Pharmacology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan

Abstract

Background: It is estimated that approximately half of the deaths in patients with HF are sudden and that the most likely causes of sudden death are lethal ventricular tachyarrhythmias such as ventricular tachycardia (VT) or fibrillation (VF). However, the precise mechanism of ventricular tachyarrhythmias remains unknown. The KCNH2 channel conducting the delayed rectifier potassium current (IKr) is recognized as the most susceptible channel in acquired long QT syndrome. Recent findings have revealed that not only suppression but also enhancement of IKr increase vulnerability to major arrhythmic events, as seen in short QT syndrome. Therefore, we investigated the existence of a circulating KCNH2 current-modifying factor in patients with HF.

Methodology/Principal Findings: We examined the effects of serum of HF patients on recombinant IKr recorded from HEK 293 cells stably expressing KCNH2 by using the whole-cell patch-clamp technique. Study subjects were 14 patients with non-ischemic HF and 6 normal controls. Seven patients had a history of documented ventricular tachyarrhythmias (VT: 7 and VF: 1). Overnight treatment with 2% serum obtained from HF patients with ventricular arrhythmia resulted in a significant enhancement in the peaks of IKr tail currents compared to the serum from normal controls and HF patients without ventricular arrhythmia.

Conclusions/Significance: Here we provide the first evidence for the presence of a circulating KCNH2 channel activator in patients with HF and ventricular tachyarrhythmias. This factor may be responsible for arhythmogenesis in patients with HF.

Citation: Sugiyama H, Nakamura K, Morita H, Akagi S, Tani Y, et al. (2011) Circulating KCNH2 Current-Activating Factor in Patients with Heart Failure and Ventricular Tachyarrhythmia. PLoS ONE 6(5): e19897. doi:10.1371/journal.pone.0019897

Editor: Christianl Schulz, Heart Center Munich, Germany

Received November 9, 2010; Accepted April 19, 2011; Published May 19, 2011

Copyright: © 2011 Sugiyama et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The authors have no support or funding to report.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: ichibun@cc.okayama-u.ac.jp

† These authors contributed equally to this work.

Introduction

Heart failure (HF) remains a major clinical problem all over the world.[1] It is estimated that approximately half of the deaths in these patients is sudden and that the most likely causes of sudden cardiac death (SCD) are lethal cardiac arrhythmia such as ventricular tachycardia (VT) or fibrillation (VF).[2] It has been known for a long time that the failing heart undergoes a complex electrical remodeling of ventricular myocytes and that a consequent reduction of repolarization reserve and electrical instability may predispose to an increased risk of life-threatening arrhythmia.[3,4]

KCNH2, also called human ether-a-go-go-related gene (hERG) potassium channel, is responsible for the rapid components of delayed rectifier potassium currents (IKr). IKr is a major contributor to the repolarization process of cardiac action potentials and is recognized as the most susceptible channel in acquired long QT syndrome.[5] Recent findings have revealed that not only suppression but also enhancement of IKr increase vulnerability to major arrhythmic events. A gain-of-function mutation in KCNH2 has also gained recognition as a congenital disorder characterized by a higher risk for major arrhythmic events and SCD, referred to as short QT syndrome (SQT).[6,7] It has also been reported that PID-118057, an IKr-activating agent, predisposes to cardiac arrhythmias in vivo.[8] HF also induces remodeling of IKr, but there is no widespread consensus on suppression or enhancement of IKr in previous studies.[9,10] Furthermore, despite the incremental progress in understanding intrinsic IKr modulators, to our knowledge, there has been no report of naturally occurring substances with a KCNH2 current-activating effect in patients with HF. Therefore, we investigated the existence of a circulating KCNH2 current-activating factor in patients with HF.

Results

Characteristics of the study subjects

Demographics and selected clinical characteristics of the HF patients are summarized in Table 1. The etiology of HF in the
study population consisted of DCM (n = 8), documented myocarditis (n = 3), dilated hypertrophic cardiomyopathy (n = 1), tachycardia-induced cardiomyopathy (n = 1) and apical ballooning syndrome (n = 1). Ventricular tachyarrhythmias were documented in 8 patients: non-sustained VT in 4 (50%), sustained VT in 3 (38%) and VF in 1 (13%). There were no significant differences in the mean age between the control group, the HF without VT and VF (VT/VF (-)) group, and the HF with VT and VF (VT/VF (+)) group (42.7 ± 14.8 yrs, 50.7 ± 10.9 yrs and 53.3 ± 10.8 yrs, respectively; P = 0.28). Male-to-female ratio was also not significantly different between the groups (2:1, 2:1 and 1:1 for the control, VT/ VF (-) and VT/VF (+) groups, respectively; P = 0.76). Mean QTc interval was longer in the overall HF patients than in the controls (0.46 ± 0.03 sec 1/2 vs. 0.42 ± 0.03 sec 1/2; P < 0.05), but there was no significant difference between the VT/VF (-) and VT/VF (+) groups (0.45 ± 0.03 sec 1/2 vs. 0.47 ± 0.02 sec 1/2; P = 0.51). Mean left ventricular ejection fraction (EF) was similar in the VT/VF (-) and VT/VF (+) groups (39 ± 11% vs. 31 ± 13%; P = 0.22).

More than half of the patients in the VT/VF (+) group took cardiotonic agents, whereas none of the patients in the VT/VF (-) group took cardiotonic agents (Table 2). However, none of the drugs, including cardiotonic agents, taken by the subjects have been reported to activate KCNH2 current.

Enhancement of KCNH2 currents by serum from HF patients with ventricular tachyarrhythmia

We investigated the effect of 2% serum of the study subjects on recombinant IKr recorded from HEK293 cells stably expressing KCNH2. KCNH2 tail currents were similar in the control and VT/VF (-) group but were significantly increased in the VT/VF (+) group (P < 0.05; VT/VF (+) vs. control and VT/VF (-)) (Figure 1). There was no significant effect on voltage dependency of KCNH2 activation in these groups (Table 3). There was no association between peak tail amplitude and EF in the overall HF patients (Figure 2).

These results indicate the presence of a circulating KCNH2 channel activator in patients with HF and ventricular tachyarhythmias.

Efficacy of class III antiarrhythmic agents

Case No.1 was treated with amiodarone, and Case No.6 was treated with d-sotalol. Both drugs, which exert their antiarrhythmic actions essentially by blocking IKr, were effective in controlling VT and VF.

Discussion

The major new finding of this work is that the factor causing activation of the KCNH2 current is present in serum of patients with HF accompanied by cardiac arrhythmia. Although there are several reports on suppression of IKr by circulating hormones or auto-antibodies, this is the first report providing evidence for a naturally occurring IKr activator.[5,11,12] IKr conducted by KCNH2 channels is the major repolarizing outward current of ventricular action potential, and it has been shown to have a strong association with life-threatening arrhythmia in many pathological circumstances. Our finding indicates that enhancement of IKr can play a key role in arrhythmogenesis in the setting of HF.

The majority of research efforts have focused classically on reduction of IKr as an approach for understanding arrhythmogenesis because it is well recognized that reduction of IKr means decrease in net repolarization current that results in prolongation of action potential duration (APD) and QT interval in the ECG and development of early afterdepolarization-induced triggered activity following torsade de pointes (TdP).[13] On the other hand, much attention has been paid to upregulation of KCNH2 in recent years because of its causal relationship to cardiac arrhythmias. SQT is a recently recognized clinical concept characterized by short QT intervals in the ECG, and it is associated with major cardiac events leading to SCD without organic heart disease.[7] The first identified form of SQT resulted from gain-of-function mutation in KCNH2. Mutation N588K in KCNH2 causes an increase in net repolarizing current.[6] In addition, recent studies have revealed a significant association between early repolarization and SQT in clinical phenotype.[14,15] Because of the high prevalence of early repolarization detected in SQT, it is thought that enhancement of repolarization is a common mechanism underlying arrhythmogenicity in early

Table 1. Clinical characteristics of the study population.

| Case No. | Age/Sex | Diagnosis                          | NYHA | LVEF (%) | Arrhythmia        | QTc (sec 1/2) |
|----------|---------|-----------------------------------|------|----------|------------------|--------------|
| 1        | 73/F    | myocarditis                       | II   | 50       | sustained VT     | 0.46         |
| 2        | 45/M    | DCM                               | II   | 11       | NSVT             | 0.47         |
| 3        | 55/F    | dilated-HCM                       | IV   | 25       | NSVT             | 0.47         |
| 4        | 37/F    | DCM                               | III  | 19       | sustained VT     | 0.48         |
| 5        | 61/F    | DCM                               | II   | 37       | NSVT             | 0.43         |
| 6        | 52/M    | myocarditis                       | II   | 42       | VF               | 0.45         |
| 7        | 48/M    | Tachycardia-induced cardiomyopathy| II   | 24       | NSVT             | 0.48         |
| 8        | 64/F    | Apical ballooning syndrome        | II   | 47       | none             | 0.43         |
| 9        | 61/F    | myocarditis                       | II   | 42       | none             | 0.48         |
| 10       | 45/M    | DCM                               | II   | 50       | none             | 0.39         |
| 11       | 55/M    | DCM                               | III  | 40       | sustained VT     | 0.51         |
| 12       | 37/F    | DCM                               | II   | 40       | none             | 0.47         |
| 13       | 55/M    | DCM                               | II   | 38       | none             | 0.47         |
| 14       | 42/M    | DCM                               | II   | 20       | none             | 0.46         |

NYHA: New York Heart Association Functional Classification, LVEF: left ventricular ejection fraction, DCM: idiopathic dilated cardiomyopathy, HCM: hypertrophic cardiomyopathy, VT: ventricular tachycardia, NSVT: non-sustained ventricular tachycardia, VF: ventricular fibrillation, QTc: corrected QT interval.
repolarization and SQT. Since QT interval is affected by other ion channels and cardiac enlargement, QT interval of HF patients with ventricular tachyarrhythmia in this study was not short. However, the circulating KCNH2 channel activator in this study is potentially responsible for electrical instability. Effects of KCNH2-activating agents have also been evaluated. It has been reported that PD-118057, established as a selective KCNH2 current enhancer without affecting activation, confers inducibility of both ventricular tachyarrhythmia and atrial fibrillation. The functional similarity between this agent and circulating KCNH2-activating factor in having no significant effect on the voltage dependence of activation suggests a causal relationship of this intrinsic enhancer with arrhythmogenesis in HF. In addition, this concept is endorsed by the efficacy of class III antiarrhythmic agents for treatment of ventricular tachyarrhythmia in the study subjects. Since the dominant action of class III antiarrhythmic agents is to lengthen the APD by a reduction of IKr, it is thought that the therapeutic effect of the agents against arrhythmia in the study subjects is manifested by offsetting oversupplied KCNH2 currents.

On the other hand, there are only a few reports on the antiarrhythmic potential of an IKr activator in specialized pathologic settings. PD-118057 prevented the early after-depolarization induced by class III antiarrhythmic agents, and NS3623 decreased the frequency of bradycardia-induced extrasystoles in vitro. However, these data were obtained only in constrained experimental conditions and couldn’t refer clinical benefit for arrhythmogenic disorders such as long QT syndrome. The mechanism by which exposure of ion channels to this factor activates the KCNH2 current remains to be elucidated. It is also uncertain whether the KCNH2-activating effect is the cause or consequence of HF-induced remodeling of action potential. However, exertion of their functional effects may be involved in arrhythmogenesis in HF. Further studies are needed to clarify these points.

In conclusion, our data show that a novel KCNH2 activator exists in serum of HF patients with ventricular tachyarrhythmia and is potentially responsible for electrical instability.

**Methods**

All of the studies were approved by the Ethics Committee of Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, and written informed consent was obtained from all patients before the procedure. The investigation also conforms to the principles outlined in the Declaration of Helsinki.

**Study population**

Serum samples were obtained from 14 HF patients referred to Okayama University Hospital, Okayama, Japan between December 2007 and December 2008 who consented to undergo evaluation of the pathogenesis of HF. HF was defined as the presence of current or previous symptoms of exercise intolerance and EF of 50% and less with no other cause of exercise intolerance. Exclusion criteria included coronary heart disease, primary valvular heart disease, severe systemic disease, or severe pulmonary disease. The mean age of the patients was 52±10 years, and 8 patients (57%) were male. Control sera were obtained from 6 subjects without cardiovascular disease or abnormal ECG.

**Table 2. Patient’s medication.**

| Case No. | Medications |
|----------|-------------|
|          | Antiarrhythmics | Beta-blockers | Diuretics | ACEI/ARB | Anticoagulant/ Antiplatelet | Cardiotonic | others |
| 1        | amiodarone | carvedilol | torasemide | candesartan | none | none | none |
| 2        | none | carvedilol | furosemide | valsartan | none | dopamine | dobutamine |
| 3        | none | carvedilol | furosemide | imidapril | none | losartan | warfarin |
| 4        | amiodarone | carvedilol | torasemide | losartan | warfarin | losartan | warfarin |
| 5        | sotalol | carvedilol | furosemide | candesartan | warfarin | losartan | warfarin |
| 6        | none | carvedilol | furosemide | valsartan | warfarin | losartan | warfarin |
| 7        | none | carvedilol | furosemide | valsartan | warfarin | losartan | warfarin |
| 8        | none | none | losartan | asiprin | none | losartan | warfarin |
| 9        | none | carvedilol | furosemide | losartan | warfarin | losartan | warfarin |
| 10       | none | none | none | none | none | none | none |
| 11       | none | carvedilol | torasemide | candesartan | warfarin | losartan | warfarin |
| 12       | none | carvedilol | torasemide | candesartan | warfarin | losartan | warfarin |
| 13       | none | carvedilol | furosemide | losartan | warfarin | losartan | warfarin |
| 14       | none | carvedilol | furosemide | candesartan | warfarin | losartan | warfarin |

ACEI/ARB: Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers.

doi:10.1371/journal.pone.0019897.t002
findings. Mean age of the control subjects was 43±15 years, and 4 subjects (67%) were male.

**Patch-clamp recordings**

KCNH2 channel currents were recorded at room temperature (22±1°C) by using the whole-cell patch-clamp technique as previously described.[11] The control bath solution contained (mM): 132 NaCl, 4.8 KCl, 1.2 MgCl₂, 2 CaCl₂, 5 glucose, 10 Hepes, pH 7.4. Pipettes (2–4 MΩ resistances) were filled with a pipette solution containing (mM): 110 potassium aspartate, 5 K₂-ATP, 11 EGTA, 5 Hepes, 1 CaCl₂, and 1 MgCl₂, pH 7.3. Currents were normalized to cell capacitance to give the measure of current density. There was no difference in membrane capacitance between the groups (14.1±2.0 pF, 14.2±2.8 pF, and 14.7±1.6 pF for the control, VT/VF (−) and VT/VF (+) groups, respectively; *P = 0.88). KCNH2 channel tail-current amplitude was monitored at 0.1 Hz by analysis of peak deactivating tail current recorded at −40 mV after 2-s depolarizing test pulses to +20 mV from a holding potential (V₉₀) of −80 mV. Current zero level (no activation) was determined by applying 25-ms pulses to −40 mV preceding the test pulses. HEK293 cells stably expressing KCNH2 were cultured for 1 day

| Table 3. Changes in voltage dependence of the KCNH2 activation. |
|---------------------------------------------------------------|
|                | Controls | VT/VF (−) | VT/VF (+) | *P  |
| V₁/₂ (mV)      | 5.6±4.8  | 3.7±3.5   | 4.3±2.5   | NS  |
| Slope factor (k)| 8.2±0.8  | 8.2±0.9   | 8.6±1.0   | NS  |

VT/VF (−): HF patients without VT and VF, VT/VF (+): HF patients with VT and VF NS indicates not significant.
doi:10.1371/journal.pone.0019897.t003

**Figure 1. Effect of serum obtained from HF patients with ventricular tachyarrhythmia on KCNH2 currents in HEK 293 cells.** A. Representative traces from a single cell cultured in a medium supplemented with 2% serum of a control subject (left) and medium supplemented with 2% serum of a patient with sustained VT (Case No. 1) (right). B. Current-voltage relationships of KCNH2 tail currents. Mean values of peak KCNH2 tail current densities were calculated by averaging the tail amplitude of each subject obtained from cells (n=8 to 11 cells) exposed to respective sera. Open circles show the results for controls (n=6), open squares show the results for HF patients without VT and VF (VT/VF (−), n=6) and closed squares show the results for HF patients with VT/VF (VT/VF (+), n=8). *P<0.05: VT/VF (+) vs. control and VT/VF (−). C. Maximum values of peak tail current in the groups. *P<0.05: VT/VF (+) vs. control and VT/VF (−). NS indicates not significant.
doi:10.1371/journal.pone.0019897.g001

**Figure 2. Relationship between peak tail amplitude and ejection fraction in the overall HF patients.**
doi:10.1371/journal.pone.0019897.g002

**Circulating KCNH2 Activating Factor in HF & VT/VF**

PLoS ONE | www.plosone.org 4 May 2011 | Volume 6 | Issue 5 | e19897
in a medium to which 2% serum obtained from the study subjects had been added. The KCNH2 current activation was studied by analysis of deactivating tail currents recorded at $-40$ mV after a series of 2-s test pulses from $-50$ mV to $+70$ mV (10 mV increments, $V_m$, $-80$ mV). Pulse frequency was 0.1 Hz. Peaks of tail currents were plotted as function of the KCNH2 activation. Activation curves were analyzed with a fit of each data to the Boltzmann equation, $I_n/I_{max} = G/G_{max} = \{1+\exp[-(V_m-V_{1/2})/k]\}^{-1}$. $G_{max}$ is normalized chord conductance at $V_m$ to the maximum chord conductance. $V_{1/2}$ is the potential where the conductance is half-maximally activated, and $k$ is the slope factor.

ECG measurements

Twelve-lead ECGs were recorded to measure the parameters of repolarization. The QT interval was measured from the start of the QRS complex to the end of the T wave, defined as the return to the iso-electric baseline. They were corrected to heart rate using Bazett’s formula: $QTc = QT / \sqrt{RR}$.

Data Analysis

All values are presented as means±D. Statistical significance was assessed with ANOVA followed by post hoc Scheffe’s method. A value of $P<.05$ was considered statistically significant. pCLAMP 9.2 software (Axon Instruments) was used to both acquire and analyze data for the patch-clamp experiments. Graphical analyses were carried out using Origin 7.0 J software (Microcal). Statistical analysis was performed with StatView 5.0 (Abacus Concepts, Inc., Berkeley, CA, U.S.A.).

Acknowledgments

The authors are grateful to Masayo Ohmori, Kaoru Akazawa, Miyuki Fujiwara, Eri Ozaki and Shizue Sugiyama for technical assistance.

Author Contributions

Conceived and designed the experiments: KN. Performed the experiments: HS KN HM YT JK TF. Analyzed the data: KN NN SN KK TM KFK HI. Contributed reagents/materials/analysis tools: JK TF. Wrote the paper: HS KN. Supervisor: TO HI.

References

1. Zipes DP (2005) Epidemiology and mechanisms of sudden cardiac death. Can J Cardiol 21 Suppl A: 37A–40A.
2. Kjekshus J (1990) Arrhythmias and mortality in congestive heart failure. Am J Cardiol 65: 428–461.
3. Janse MJ (2004) Electrophysiological changes in heart failure and their relationship to arrhythmogenesis. Cardiovasc Res 61: 208–217.
4. Tomaselli GF, Zipes DP (2008) Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome. J Am Coll Cardiol 50: 1808–1809.
5. Nakamura K, Katayama Y, Kasano KF, Harada K, Tani Y, et al. (2007) Anti-KCNH2 antibody-induced long QT syndrome: novel acquired form of long QT syndrome. J Am Coll Cardiol 50: 1808–1809.
6. Cordeiro JM, Brugada R, Wu YS, Hong K, Dumaine R (2005) Modulation of I(Kr) inactivation by mutation N588K in KCNH2: a link to arrhythmogenesis in short QT syndrome. Cardiovasc Res 67: 498–509.
7. Gussak I, Brugada P, Brugada J, Wright RS, Kopecky SL, et al. (2000) Anti-KCNH2 current suppresses bradycardia-induced triggered activity in isolated canine hearts. Am J Physiol Heart Circ Physiol 283: H1031–1041.
8. Patel C, Antzelevitch C (2008) Cellular basis for atrial fibrillation in an experimental model of short QT1: implications for a pharmacological approach to therapy. Heart Rhythm 5: 583–590.
9. Tsuji Y, Ophof T, Kamiya K, Yasui K, Liu W, et al. (2000) Pacing-induced heart failure causes a reduction of delayed rectifier potassium currents along with decreases in calcium and transient outward currents in rabbit ventricle. Cardiovasc Res 46: 300–309.
10. Li GR, Lau CP, Ducharme A, Tarasfi JC, Natel S (2002) Transmural action potential andionic current remodeling in ventricles of failing canine hearts. Am J Physiol Heart Circ Physiol 283: H1031–1041.
11. Kurokawa J, Tamagawa M, Harada N, Honda S, Bui CX, et al. (2008) Acute effects of oestrogen on the guinea pig and human I(Kr) channels and drug-induced prolongation of cardiac repolarization. J Physiol 596: 2961–2973.
12. Wian YH, Shu GX, Dong F, Sheng JW, Xu YF (2008) Inhibition of the delayed rectifier potassium current in ventricular myocytes by angiotensin II via the AT1 receptor. Br J Pharmacol 154: 429–439.
13. Saenen JB, Vrints CJ (2008) Molecular aspects of the congenital and acquired Long QT Syndrome: clinical implications. J Mol Cell Cardiol 44: 633–646.
14. Watanabe H, Makijaszek T, Koyama T, Kannankeril PJ, Seto S, et al. (2010) High prevalence of early repolarization in short QT syndrome. Heart Rhythm 7: 647–652.
15. Haissaguerre M, Derval N, Sacher F, Jesel L, Deisenhofer I, et al. (2008) Sudden cardiac arrest associated with early repolarization. N Engl J Med 358: 2016–2023.
16. NoF E, Burashnikov A, Antzelevitch C (2010) Cellular basis for atrial fibrillation in an experimental model of short QT1: implications for a pharmacological approach to therapy. Heart Rhythm 7: 241–257.
17. Zhou J, Augelli-Staafan CE, Bradley JA, Chen X, Koci BJ, et al. (2005) Novel human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity. Mol Pharmacol 68: 876–884.
18. Hansen RS, Olesen SP, Grunnet M (2007) Pharmacological activation of rapid delayed rectifier potassium current suppresses bradycardia-induced triggered activity in the isolated guinea pig heart. J Pharmacol Exp Ther 321: 996–1002.